Fan Yang-Hua, Fang Hua, Ji Chen-Xing, Xie Huan, Xiao Bing, Zhu Xin-Gen
Department of Neurosurgery, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Department of Neurosurgery, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Clin Chim Acta. 2017 Mar;466:120-126. doi: 10.1016/j.cca.2017.01.016. Epub 2017 Jan 13.
It has been reported that Colon cancer-associated transcript 2 (CCAT2) is dysregulated in various cancers. We performed this meta-analysis to clarify its promising functions as a prognosis marker in malignant tumors.
Electronic databases, including PubMed, Medline, OVID, Cochrane Library, and Web of Science, were searched from inception to October 20, 2016. The hazard ratio (HR) and 95% confidence interval (CI) were calculated to explore the relationship between CCAT2 expression and survival, which were extracted from the eligible studies. The odds ratio (OR) was calculated to assess the association between CCAT2 expression and pathological parameters using RevMan5.3 software.
Six original studies were included in this meta-analysis including 725 cancer patients. The pooled HR suggested that high CCAT2 expression was significantly correlated with overall survival (OS) (HR=2.30, 95% CI: 1.62-3.25, p<0.00001) in cancer patients. Subgroup analysis revealed a significant association between CCAT2 and OS in urogenital system (HR=1.70, 95% CI: 1.27-2.26, p<0.003) and non-urogenital system cancer patients (HR=3.18, 95% CI: 2.09-4.83, p<0.0001). A significant association was observed between high CCAT2 expression and poor progression-free survival (PFS) in cancer patients (pooled HR=2.76, 95% CI: 1.74-4.37). CCAT2 expression was significantly related to lymph node metastasis (LNM) (OR=4.33, 95% CI 2.03-9.22), distant metastasis (DM) (OR=11.66, 95% CI: 5.36-25.37) and tumor stage (OR=2.58, 95% CI 1.86-3.57).
This meta-analysis demonstrated that high CCAT2 expression significantly predicts poor OS, poor PFS, LNM, DM and tumor stage, suggesting that high CCAT2 expression may serve as a novel biomarker for poor prognosis and metastasis in cancers.
据报道，结肠癌相关转录本2（CCAT2）在多种癌症中表达失调。我们进行了这项荟萃分析，以阐明其作为恶性肿瘤预后标志物的潜在作用。
检索电子数据库，包括PubMed、Medline、OVID、Cochrane图书馆和Web of Science，检索时间从建库至2016年10月20日。计算风险比（HR）和95%置信区间（CI），以探讨CCAT2表达与生存之间的关系，这些数据从符合条件的研究中提取。使用RevMan5.3软件计算比值比（OR），以评估CCAT2表达与病理参数之间的关联。
该荟萃分析纳入了6项原始研究，共725例癌症患者。汇总的HR表明，癌症患者中CCAT2高表达与总生存期（OS）显著相关（HR=2.30，95%CI：1.62-3.25，p<0.00001）。亚组分析显示，CCAT2与泌尿生殖系统癌症患者（HR=1.70，95%CI：1.27-2.26，p<0.003）和非泌尿生殖系统癌症患者的OS显著相关（HR=3.18，95%CI：2.09-4.83，p<0.0001）。癌症患者中CCAT2高表达与无进展生存期（PFS）差显著相关（汇总HR=2.76，95%CI：1.74-4.37）。CCAT2表达与淋巴结转移（LNM）（OR=4.33，95%CI 2.03-9.22）、远处转移（DM）（OR=11.66，95%CI：5.36-25.37）和肿瘤分期（OR=2.58，95%CI 1.86-3.57）显著相关。
这项荟萃分析表明，CCAT2高表达显著预示着OS差、PFS差、LNM、DM和肿瘤分期，提示CCAT2高表达可能作为癌症预后不良和转移的一种新型生物标志物。
